SPT Business Summary

ScinoPharm Taiwan (SPT) is a leading global specialty pharmaceutical company that generates revenue through the development, manufacture, and sale of high-barrier active pharmaceutical ingredients (APIs), finished dosage formulations, and contract development and manufacturing organization (CDMO) services. The company operates across three primary business segments: Proprietary Generic APIs, which includes over 70 registered products with a dominant position in oncology; Proprietary Formulations, focusing on high-value drug-device combinations and sterile injectables; and CDMO Services, specializing in complex peptides, steroids, and cytotoxic compounds. As of 2026, SPT has significantly expanded its footprint in the GLP-1 peptide market for metabolic disorders and secured critical domestic approvals for oncology treatments like Bortezomib. In the competitive landscape, SPT contends with regional and global peers such as TTY Biopharm, Synmosa Biopharma, and Panion & BF Biotech, distinguishing itself through its vertically integrated API-to-injectable capabilities and a reputation for zero-deficiency FDA compliance. SPT was founded in 1997 by veteran pharmaceutical executives Jo Shen and Hardy W. Chan, both former high-level leaders at Syntex. The current leadership team is headed by Chairman and General Chief Strategy Officer Chih-Hsien Lo, who also chairs the Uni-President Group, and President and CEO Li-An Lu (Susan Lu), who has led the company’s strategic pivot toward finished dosages and CDMO growth since 2021. Technical innovation is overseen by Li-Chiao Chang, the Vice President of R&D and Chief Scientific Officer. The company maintains a robust institutional backing, with major shareholders including the Uni-President Enterprises Corp (37.94%), the National Development Fund of the Executive Yuan (13.85%), and the Taiwan Sugar Corporation (4.12%), ensuring long-term capital stability and strategic alignment with Taiwan's pharmaceutical supply chain resilience policies.